Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples